A detailed history of Palo Alto Investors LP transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Palo Alto Investors LP holds 811,268 shares of TSHA stock, worth $1.72 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
811,268
Previous 811,268 -0.0%
Holding current value
$1.72 Million
Previous $1.82 Million 10.29%
% of portfolio
0.22%
Previous 0.23%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.43 - $3.25 $402,412 - $914,572
281,407 Added 53.11%
811,268 $2.33 Million
Q4 2023

Feb 14, 2024

BUY
$1.33 - $2.88 $704,715 - $1.53 Million
529,861 New
529,861 $937,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $103M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Palo Alto Investors LP Portfolio

Follow Palo Alto Investors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Palo Alto Investors LP with notifications on news.